{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transplant+Glomerulopathy",
    "query": {
      "condition": "Transplant Glomerulopathy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T03:38:55.652Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03832114",
      "title": "Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glomerulonephritis"
      ],
      "interventions": [
        {
          "name": "LNP023",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2019-02-20",
      "completion_date": "2021-04-23",
      "has_results": true,
      "last_update_posted_date": "2024-01-30",
      "last_synced_at": "2026-06-10T03:38:55.652Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03832114"
    },
    {
      "nct_id": "NCT02546492",
      "title": "Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Transplant Glomerulopathy"
      ],
      "interventions": [
        {
          "name": "Acthar gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 6,
      "start_date": "2016-08",
      "completion_date": "2021-05-27",
      "has_results": true,
      "last_update_posted_date": "2022-10-06",
      "last_synced_at": "2026-06-10T03:38:55.652Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02546492"
    },
    {
      "nct_id": "NCT03380962",
      "title": "Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Failure, Chronic",
        "End-Stage Renal Disease",
        "Transplant Glomerulopathy",
        "Transplant;Failure,Kidney",
        "Kidney Transplant Failure and Rejection",
        "Antibody-mediated Rejection",
        "Kidney Transplant; Complications"
      ],
      "interventions": [
        {
          "name": "Clazakizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanley Jordan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "15 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2018-02-27",
      "completion_date": "2025-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-03-24",
      "last_synced_at": "2026-06-10T03:38:55.652Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03380962"
    },
    {
      "nct_id": "NCT04572854",
      "title": "Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "C3G",
        "IC-MPGN",
        "Renal Transplant",
        "Complement 3 Glomerulopathy",
        "Complement 3 Glomerulopathy (C3G)",
        "Dense Deposit Disease (DDD)",
        "Membranoproliferative Glomerulonephritis",
        "Membranoproliferative Glomerulonephritis (MPGN)",
        "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)",
        "C3 Glomerulopathy",
        "C3 Glomerulonephritis",
        "Complement 3 Glomerulonephritis"
      ],
      "interventions": [
        {
          "name": "Pegcetacoplan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2021-09-07",
      "completion_date": "2026-01-20",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-06-10T03:38:55.652Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04572854"
    },
    {
      "nct_id": "NCT03607500",
      "title": "Effect of Moderate Caloric Restriction on Glomerular Growth After Kidney Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Transplant; Complications",
        "Glomerular Disease",
        "Weight Gain",
        "Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "caloric intake reduction",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1,
      "start_date": "2019-08-22",
      "completion_date": "2021-08-16",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-06-10T03:38:55.652Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03607500"
    },
    {
      "nct_id": "NCT03380377",
      "title": "Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Antibody-mediated Rejection",
        "Kidney Transplant; Complications",
        "Transplant Glomerulopathy",
        "Transplant Glomerulopathy - Late Form",
        "Transplant Glomerulopathy - Early Form",
        "Kidney Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "Clazakizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanley Jordan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "15 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2018-02-21",
      "completion_date": "2024-04-16",
      "has_results": true,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-06-10T03:38:55.652Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03380377"
    },
    {
      "nct_id": "NCT00446459",
      "title": "Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Failure, Chronic",
        "Diabetic Nephropathies",
        "Glomerulonephritis, IGA",
        "Hypertension, Renal"
      ],
      "interventions": [
        {
          "name": "mycophenolate mofetil (CellCept)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 45,
      "start_date": "2006-04",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2010-04-15",
      "last_synced_at": "2026-06-10T03:38:55.652Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00446459"
    },
    {
      "nct_id": "NCT02057523",
      "title": "Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Proteinuria",
        "Transplant Glomerulopathy"
      ],
      "interventions": [
        {
          "name": "Acthar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 2,
      "start_date": "2014-09",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2020-09-04",
      "last_synced_at": "2026-06-10T03:38:55.652Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02057523"
    },
    {
      "nct_id": "NCT03316521",
      "title": "First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Complement Mediated Diseases"
      ],
      "interventions": [
        {
          "name": "AMY-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amyndas Pharmaceuticals S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "18 Years to 60 Years · Male only"
      },
      "enrollment_count": 50,
      "start_date": "2017-04-24",
      "completion_date": "2017-11-30",
      "has_results": false,
      "last_update_posted_date": "2018-01-16",
      "last_synced_at": "2026-06-10T03:38:55.652Z",
      "location_count": 1,
      "location_summary": "High Point, North Carolina",
      "locations": [
        {
          "city": "High Point",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03316521"
    }
  ]
}